Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (5)
  • Open Access


    Analysis of the personalized treatment and the relevant prognostic factors in children with medulloblastoma


    BIOCELL, Vol.47, No.5, pp. 1065-1073, 2023, DOI:10.32604/biocell.2023.025924

    Abstract Purpose: The present study summarized cases of children (n = 32) with medulloblastoma (MB) who were treated using stratified therapy based on risk grading and also discussed the factors affecting prognosis. Methods: According to the risk stratification criteria, the cases were divided into the following four risk groups: low, standard, high, and very high. The 5-year overall survival (OS) and progression-free survival (PFS) rates were summarized. Further, the effects on the prognosis of tumor size, tumor stage, degree of resection, treatment mode, metastatic recurrence, molecular typing, and risk stratification were analyzed. Results: In the present study, following… More >

  • Open Access


    Development and Validation of a Nomogram Model to Predict the Prognosis of Intrahepatic Cholangiocarcinoma

    Yi Chen1,#, Liyun Huang1,#, Zuwu Wei1, Xiaoling Liu1, Lihong Chen1,2,*, Bin Wang1,2,*

    Oncologie, Vol.24, No.2, pp. 329-340, 2022, DOI:10.32604/oncologie.2022.022521

    Abstract Background: The effective method for predicting prognosis of ICC is still lack. This study aims to establish and verify an effective prognostic nomogram model for intrahepatic cholangiocarcinoma (ICC) after partial hepatectomy. Materials and Methods: A nomogram model was developed in a cohort of 127 patients from January 2015 to December 2019. General clinical characteristics including preoperative physical examination data and postoperative pathological features were obtained. The independent risk factors identified by univariate and multivariate COX proportional hazards regression models were used to construct nomogram model. Predictive accuracy and discriminative ability were determined using a concordance index and… More >

  • Open Access


    Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization by CalliSpheres® in 275 Hepatocellular Carcinoma Patients: Results From the Chinese CalliSpheres® Transarterial Chemoembolization in Liver Cancer (CTILC) Study

    Junhui Sun*1, Guanhui Zhou*1, Xiaoxi Xie, Wenjiang Gu, Jing Huang§, Dedong Zhu, Wenhao Hu#, Qinming Hou**, Changsheng Shi††, Tiefeng Li‡‡ , Xin Zhang§§, Wenbin Ji¶¶, Shihong Ying§§, Zhiyi Peng§§, Jian Zhou##, Zhihai Yu***, Jiansong Ji†††, Haijun Du‡‡‡, Xiaohua Guo§§§, Jian Fang¶¶¶, Jun Han###, Huanhai Xu****, Zhichao Sun††††, Wenqiang Yu‡‡‡‡, Guoliang Shao§§§§, Xia Wu¶¶¶¶ ,Hongjie Hu¶¶¶¶ , Ling Li#, Jiaping Zheng§§§§, Jun Luo§§§§, Yutang Chen§§§§, Guohong Cao####, Tingyang Hu‡‡‡‡

    Oncology Research, Vol.28, No.1, pp. 75-94, 2020, DOI:10.3727/096504019X15662966719585

    Abstract The purpose of this study was to investigate the efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) treatment in Chinese hepatocellular carcinoma (HCC) patients and the prognostic factors for treatment response as well as survival. A total of 275 HCC patients were included in this prospective study. Treatment response was assessed by modified Response Evaluation Criteria in Solid Tumors (mRECIST), and progression-free survival (PFS) as well as overall survival (OS) were determined. Liver function and adverse events (AEs) were assessed before and after DEB-TACE operation. Complete response (CR), partial response (PR), and objective response… More >

  • Open Access


    Outcomes of Patients With Acute Myeloid Leukemia Who Relapse After 5 Years of Complete Remission

    Arisha Patel, Mounzer Agha, Anastasios Raptis, Jing-Zhou Hou, Rafic Farah, Robert L. Redner, Annie Im, Kathleen A. Dorritie, Alison Sehgal, James Rossetti, Melissa Saul, Daniel Normolle, Konstantinos Lontos, Michael Boyiadzis

    Oncology Research, Vol.28, No.7-8, pp. 811-814, 2020, DOI:10.3727/096504020X15965357399750

    Abstract Leukemia relapse 5 years after achieving first complete remission (CR1) is uncommon in patients with acute myeloid leukemia (AML). In this study, we evaluated the outcomes of AML patients with late relapse at our institution and reviewed the literature for these patients. The study cohort consisted of nine AML patients with late relapse. The median interval between CR1 and AML relapse was 6.1 years (range: 5.1–16.2 years). At relapse, the karyotype was different from the initial AML diagnosis in 50% of patients. At the time of AML relapse, seven patients received induction chemotherapy and two More >

  • Open Access


    Analysis of the Effects of Different Surgical Procedures for the Treatment of Thyroid Cancer on the Expression Levels of IL-17, IL-35, and SIL-2R and the Prognostic Factors

    Chuanwei Xu1, Renju Ding2, Chuanping Xu3,*

    Oncologie, Vol.22, No.1, pp. 43-51, 2020, DOI:10.32604/oncologie.2020.012445

    Abstract To analyze the effects of different surgical procedures for the treatment of thyroid cancer on the expression levels of serum interleukin-17 (IL-17), IL-35, soluble interleukin-2 receptor (SIL-2R), and the prognostic factors. Seventy-eight patients with differentiated thyroid cancer were selected and grouped as control group (CG) (n = 39, underwent subtotal thyroidectomy) and observation group (OG) (n = 39, underwent total thyroidectomy). The serum IL-17, IL-35, and SIL- 2R expression levels; the incidence of complications; and the differentiated thyroid carcinoma (DTC) relapse rate were compared between the two groups. The serum IL-17 and SIL-2R levels were… More >

Displaying 1-10 on page 1 of 5. Per Page